Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pavinetant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 known ✓ | P29371 | 20/20 | 1.00 |
| ▸ | TACR2 | P21452 | 6/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pavinetant SCHEMBL29375128 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Pavinetant SCHEMBL17132260 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3590211 | 0.88 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4665567 | 0.88 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18407125 | 0.87 | TACR3 (0.80) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472992 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1582141 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472989 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1580864 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12049917 | 0.85 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289705-A1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA SA (BE) | 2018-10-11 | — | — | US | claimed |
| US-20170157109-A1 | NK3 RECEPTOR ANTAGONIST COMPOUND (NK3RA) FOR USE IN A METHOD FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS) | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | US | claimed |
| US-9475773-B2 | NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) | ASTRAZENECA AB (SE) | 2016-10-25 | — | — | US | claimed |
| EP-1968944-B1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2016-04-20 | — | — | EP | claimed |
| US-20160083350-A1 | A NK3 RECEPTOR ANTAGONIST COMPOUND (NK3RA) FOR USE IN A METHOD FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS) | ASTRAZENECA UK LIMITED (GB) | 2016-03-24 | — | — | US | claimed |
| EP-3704271-B1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12458641-B2 | NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | OGEDA SA (BE) | 2025-11-04 | — | — | US | disclosed |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-02-20 | — | — | US | disclosed |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3271015-B1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA S A (BE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3271015-B1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA S A (BE) | 2023-09-27 | — | — | EP | disclosed |
| US-20230128029-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021062-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TACR3 1038/4885TACR2 730/4885CYP1A2 73/4885 |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | TACR3 673/4885TACR2 581/4885CYP1A2 170/4885 |
| US-20230128029-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-12458641-B2 | NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | MC3R, ACKR3, PROKR1 | TACR3 24/4885TACR2 9/4885CYP1A2 4482/4885 |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-20180289705-A1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | ADORA3, CSF3R, ACKR3 | TACR3 8/4885TACR2 4/4885CYP1A2 3557/4885 |
| US-20160083350-A1 | A NK3 RECEPTOR ANTAGONIST COMPOUND (NK3RA) FOR USE IN A METHOD FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS) | PKD1, FSHR, KLK13 | TACR3 24/4885TACR2 16/4885CYP1A2 4264/4885 |
| US-20170157109-A1 | NK3 RECEPTOR ANTAGONIST COMPOUND (NK3RA) FOR USE IN A METHOD FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS) | PKD1, FSHR, GNRHR | TACR3 25/4885TACR2 17/4885CYP1A2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.